Related references
Note: Only part of the references are listed.COX-2 induces oncogenic micro RNA miR655 in human breast cancer
Mousumi Majumder et al.
SCIENTIFIC REPORTS (2018)
Prostaglandin receptors induce urothelial tumourigenesis as well as bladder cancer progression and cisplatin resistance presumably via modulating PTEN expression
Eiji Kashiwagi et al.
BRITISH JOURNAL OF CANCER (2018)
Epigenetic activation of the prostaglandin receptor EP4 promotes resistance to endocrine therapy for breast cancer
J. F. Hiken et al.
ONCOGENE (2017)
EP4 receptor promotes invadopodia and invasion in human breast cancer
Felix Tonisen et al.
EUROPEAN JOURNAL OF CELL BIOLOGY (2017)
Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1
Francois Bertucci et al.
CURRENT ONCOLOGY REPORTS (2017)
Structural features of subtype-selective EP receptor modulators
Tijana Markovic et al.
DRUG DISCOVERY TODAY (2017)
Discovery of AAT-008, a novel, potent, and selective prostaglandin EP4 receptor antagonist
Yoshiyuki Okumura et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2017)
PGE2 promotes breast cancer-associated lymphangiogenesis by activation of EP4 receptor on lymphatic endothelial cells
Pinki Nandi et al.
BMC CANCER (2017)
Upregulation of the S1P3 receptor in metastatic breast cancer cells increases migration and invasion by induction of PGE2 and EP2/EP4 activation
Iuliia Filipenko et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2016)
The Roles of EP4 Prostanoid Receptors in Cancer Malignancy Signaling
Hiromichi Fujino
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2016)
G protein-coupled receptors as promising cancer targets
Ying Liu et al.
CANCER LETTERS (2016)
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
Weiping Zou et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
COX-2 Induces Breast Cancer Stem Cells via EP4/PI3K/AKT/NOTCH/WNT Axis
Mousumi Majumder et al.
STEM CELLS (2016)
Upregulation of Cyclooxygenase-2/Prostaglandin E2 (COX-2/PGE2) Pathway Member Multiple Drug Resistance-Associated Protein 4 (MRP4) and Downregulation of Prostaglandin Transporter (PGT) and 15-Prostaglandin Dehydrogenase (15-PGDH) in Triple-Negative Breast Cancer
Tyler J. Kochel et al.
BREAST CANCER-BASIC AND CLINICAL RESEARCH (2016)
Prostaglandin E2 and the EP receptors in malignancy: possible therapeutic targets?
G. O'Callaghan et al.
BRITISH JOURNAL OF PHARMACOLOGY (2015)
ER-886046, an antagonist of PGE2 receptor type-4, induces an effective antitumor immune response in mice by attenuating intratumoral MDSCs and TAMs
Diana I. Albu et al.
CANCER RESEARCH (2015)
COX-2 Elevates Oncogenic miR-526b in Breast Cancer by EP4 Activation
Mousumi Majumder et al.
MOLECULAR CANCER RESEARCH (2015)
Antagonists of PD-1 and PD-L1 in Cancer Treatment
Evan J. Lipson et al.
SEMINARS IN ONCOLOGY (2015)
Combination of EP4 antagonist and checkpoint inhibitors promotes anti-tumor effector T cells in preclinical tumor models
Xingfeng Bao et al.
Journal for ImmunoTherapy of Cancer (2015)
Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer
Jiabei He et al.
SCIENTIFIC REPORTS (2015)
Prostaglandin E receptor EP4 is a therapeutic target in breast cancer cells with stem-like properties
Namita Kundu et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Prostaglandin E2 receptor EP4 as the common target on cancer cells and macrophages to abolish angiogenesis, lymphangiogenesis, metastasis, and stem-like cell functions
Mousumi Majumder et al.
CANCER SCIENCE (2014)
An EP4 Antagonist ONO-AE3-208 Suppresses Cell Invasion, Migration, and Metastasis of Prostate Cancer
Song Xu et al.
CELL BIOCHEMISTRY AND BIOPHYSICS (2014)
Cyclooxygenase-2 expression in non-metastatic triple-negative breast cancer patients
Kailash Mosalpuria et al.
MOLECULAR AND CLINICAL ONCOLOGY (2014)
Cyclooxygenase-2 up-regulates CCR7 expression via AKT-mediated phosphorylation and activation of Sp1 in breast cancer cells
Chun-Wei Chuang et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2013)
E-type prostanoid receptor 4 (EP4) in disease and therapy
Viktoria Konya et al.
PHARMACOLOGY & THERAPEUTICS (2013)
A prostaglandin E (PGE) receptor EP4 antagonist protects natural killer cells from PGE2-mediated immunosuppression and inhibits breast cancer metastasis
Xinrong Ma et al.
ONCOIMMUNOLOGY (2013)
Cancer Stem Cells: Current Status and Evolving Complexities
Jane E. Visvader et al.
CELL STEM CELL (2012)
Personalized Medicine in Breast Cancer: A Systematic Review
Sang-Hoon Cho et al.
JOURNAL OF BREAST CANCER (2012)
Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast cancer model
Xiping Xin et al.
LABORATORY INVESTIGATION (2012)
Selective cyclooxygenase-2 (COX-2) inhibitors and breast cancer risk
Varun Ashok et al.
BREAST (2011)
Prostaglandin E2 EP receptors as therapeutic targets in breast cancer
Jocelyn Reader et al.
CANCER AND METASTASIS REVIEWS (2011)
The role of the EP receptors for prostaglandin E2 in skin and skin cancer
J. E. Rundhaug et al.
CANCER AND METASTASIS REVIEWS (2011)
Prostaglandin E2 (PGE2) suppresses natural killer cell function primarily through the PGE2 receptor EP4
Dawn Holt et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
G protein-coupled receptors: novel targets for drug discovery in cancer
Rosamaria Lappano et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Circulating microRNAs as Novel Minimally Invasive Biomarkers for Breast Cancer
Helen M. Heneghan et al.
ANNALS OF SURGERY (2010)
Differential Regulation of the Aggressive Phenotype of Inflammatory Breast Cancer Cells by Prostanoid Receptors EP3 and EP4
Fredika M. Robertson et al.
CANCER (2010)
Relationship between cyclooxygenase-2 and human epidermal growth factor receptor 2 in vascular endothelial growth factor C up-regulation and lymphangiogenesis in human breast cancer
Rabindra N. Bhattacharjee et al.
CANCER SCIENCE (2010)
Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis
Nobuyoshi Kosaka et al.
CANCER SCIENCE (2010)
A role for COX2-derived PGE2 and PGE2-receptor subtypes in head and neck squamous carcinoma cell proliferation
Aline Correa Abrahao et al.
ORAL ONCOLOGY (2010)
Tumor-Initiating and -Propagatin Cells: Cells That We Would Like to Identify and Control
Berit Bolge Tysnes
NEOPLASIA (2010)
The COX-2/PGE(2) pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment
Alexander Greenhough et al.
CARCINOGENESIS (2009)
Pharmacological activation of the prostaglandin E-2 receptor EP4 improves cardiac function after myocardial ischaemia/reperfusion injury
Keiichi Hishikari et al.
CARDIOVASCULAR RESEARCH (2009)
Aberrant crypt foci: are they intermediate endpoints of colon carcinogenesis in humans?
Akshay K. Gupta et al.
CURRENT OPINION IN GASTROENTEROLOGY (2009)
Regulation of EP receptors in non-small cell lung cancer by epigenetic modifications
Steven G. Gray et al.
EUROPEAN JOURNAL OF CANCER (2009)
High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability
Alysha K. Croker et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2009)
Cyclooxygenase-2 up-regulates CCR7 via EP2/EP4 receptor signaling pathways to enhance lymphatic invasion of breast cancer cells
Mei-Ren Pan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Cyclooxygenase-2-linked attenuation of hypoxia-induced pulmonary hypertension and intravascular thrombosis
Mary-Clare Cathcart et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy
Xiaoxian Li et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Roles of eicosanoids in prostate cancer
Kasem Nithipatikom et al.
FUTURE LIPIDOLOGY (2008)
Prostaglandin E receptors
Yukihiko Sugimoto et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Prostaglandin E receptor EN antagonist suppresses osteolysis due to bone metastasis of mouse malignant melanoma cells
Morichika Takita et al.
FEBS LETTERS (2007)
Inflammation and breast cancer - Cyclooxygenase/prostaglandin signaling and breast cancer
Louise R. Howe
BREAST CANCER RESEARCH (2007)
MicroRNA signatures in human cancers
George A. Calin et al.
NATURE REVIEWS CANCER (2006)
Concordance among gene-expression-based predictors for breast cancer
Cheng Fan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
E prostanoid 2 (EP2)/EP4-mediated suppression of antigen-specific human T-cell responses by prostaglandin E2
Mitsuhiro Okano et al.
IMMUNOLOGY (2006)
HER-2/neu status is a determinant of mammary aromatase activity in vivo:: Evidence for a cyclooxygenase-2-dependent mechanism
Kotha Subbaramaiah et al.
CANCER RESEARCH (2006)
COX-2-mediated stimulation of the lymphangiogenic factor VEGF-C in human breast cancer
AV Timoshenko et al.
BRITISH JOURNAL OF CANCER (2006)
Oncomirs - microRNAs with a role in cancer
A Esquela-Kerscher et al.
NATURE REVIEWS CANCER (2006)
Increased EP4 receptor expression in colorectal cancer progression promotes cell growth and anchorage independence
SD Chell et al.
CANCER RESEARCH (2006)
Cancer stem cells: An old idea - A paradigm shift
MS Wicha et al.
CANCER RESEARCH (2006)
Role of β-arrestin 1 in the metastatic progression of colorectal cancer
FG Buchanan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors
RE Harris et al.
BMC CANCER (2006)
Prostaglandin E receptor EP3 deficiency modifies tumor outcome in mouse two-stage skin carcinogenesis
Y Shoji et al.
CARCINOGENESIS (2005)
HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice
LR Howe et al.
CANCER RESEARCH (2005)
Cardiospecific overexpression of the prostaglandin EP3 receptor attenuates ischemia-induced myocardial injury
M Martin et al.
CIRCULATION (2005)
Cyclooxygenase-2 and epidermal growth factor receptor: Pharmacologic targets for chemoprevention
AJ Dannenberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Cyclooxygenase-2 is essential for HER2/neu to suppress N-(4-hydroxyphenyl)retinamide apoptotic effects in breast cancer cells
AM Simeone et al.
CANCER RESEARCH (2004)
PGE2-mediated upregulation of iNOS in murine breast cancer cells through the activation of EP4 receptors
AV Timoshenko et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Cyclooxygenase isozymes: The biology of prostaglandin synthesis and inhibition
DL Simmons et al.
PHARMACOLOGICAL REVIEWS (2004)
Role of prostaglandin E2 receptors in migration of murine and human breast cancer cells
AV Timoshenko et al.
EXPERIMENTAL CELL RESEARCH (2003)
Prostaglandin E2 modulates dendritic cell function via EP2 and EP4 receptor subtypes
H Harizi et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2003)
Prostaglandin E2 induced functional expression of early growth response factor-1 by EP4, but not EP2, prostanoid receptors via the phosphatidylinositol 3-kinase and extracellular signal-regulated kinases
H Fujino et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Prospective identification of tumorigenic breast cancer cells
M Al-Hajj et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
COX-2 inhibitors for the prevention of breast cancer
LR Howe et al.
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA (2003)
Roles of prostaglandin I2 and thromboxane A2 in cardiac ischemia-reperfusion injury -: A study using mice lacking their respective receptors
CY Xiao et al.
CIRCULATION (2001)
Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis
JG Rozic et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice
CH Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Prostanoid receptors: Subtypes and signaling
RM Breyer et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY (2001)
Selective activation of E-type prostanoid3-receptors reduces myocardial infarct size -: A novel insight into the cardioprotective effects of prostaglandins
C Thiemermann et al.
PHARMACOLOGY & THERAPEUTICS (2000)
Share Paper
